Once-daily oral dosing: a future boon for patients with DMO, GA, kidney disease
A once-daily oral drug targets inflammatory processes and thus far has been found to be well tolerated in a Phase 2 safety trial.
What to expect at Angiogenesis 2022: Fruitful discussion, revolutionary therapies
Ophthalmologists gather to discuss neovascular and exudative diseases of the eye and the revolutionary therapies on the horizon.
